You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

CLINICAL TRIALS PROFILE FOR AMOXICILLIN; VONOPRAZAN FUMARATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Amoxicillin; Vonoprazan Fumarate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT04901117 ↗ Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days Not yet recruiting Heze Municipal 3rd people's hospital Phase 4 2021-06-01 The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗ Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days Not yet recruiting Jining No.2 People's Hospital Phase 4 2021-06-01 The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗ Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days Not yet recruiting Maternity and Child Care Health Center of Dezhou Phase 4 2021-06-01 The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗ Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days Not yet recruiting PKUcare luzhong hospital Phase 4 2021-06-01 The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗ Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days Not yet recruiting Qihe County City Hospital Phase 4 2021-06-01 The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗ Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days Not yet recruiting Qilu Hospital of Shandong University Phase 4 2021-06-01 The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Amoxicillin; Vonoprazan Fumarate

Condition Name

Condition Name for Amoxicillin; Vonoprazan Fumarate
Intervention Trials
Helicobacter Pylori Infection 4
Helicobacter Pylori Eradication Rate 2
Helicobacter Pylori 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Amoxicillin; Vonoprazan Fumarate
Intervention Trials
Infections 1
Helicobacter Infections 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Amoxicillin; Vonoprazan Fumarate

Trials by Country

Trials by Country for Amoxicillin; Vonoprazan Fumarate
Location Trials
China 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Amoxicillin; Vonoprazan Fumarate

Clinical Trial Phase

Clinical Trial Phase for Amoxicillin; Vonoprazan Fumarate
Clinical Trial Phase Trials
Phase 4 5
Phase 3 1
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Amoxicillin; Vonoprazan Fumarate
Clinical Trial Phase Trials
Not yet recruiting 5
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Amoxicillin; Vonoprazan Fumarate

Sponsor Name

Sponsor Name for Amoxicillin; Vonoprazan Fumarate
Sponsor Trials
Sixth Affiliated Hospital, Sun Yat-sen University 2
The First Affiliated Hospital of Nanchang University 2
Heze Municipal 3rd people's hospital 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Amoxicillin; Vonoprazan Fumarate
Sponsor Trials
Other 36
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.